Peptide Synthesis Explained: How Therapeutic Peptides Are Made

Peptide synthesis is the chemical process of linking amino acids together with peptide bonds to build a defined sequence. The dominant method is solid-phase peptide synthesis, or SPPS, which assembles peptides one amino acid at a time on a resin. Modern peptide drugs such as semaglutide and tirzepatide are made at pharmaceutical scale using controlled manufacturing and quality testing [1,2,3].

What is peptide synthesis?

Peptide synthesis means building a peptide by connecting amino acids in a specific order. A peptide is a short chain of amino acids, while a protein is usually longer and folds into a more complex shape [1,2].

Each amino acid has chemical groups that can react with other amino acids. Chemists use protecting groups to block some reactive sites so the next amino acid attaches in the right place. This control matters because even one amino-acid change can alter a peptide’s identity, potency, or safety [2,3].

How a peptide bond forms

A peptide bond forms when the carboxyl group of one amino acid links to the amino group of another. In the lab, coupling reagents help drive this reaction forward and reduce unwanted side reactions [2,3].

In living cells, ribosomes build proteins from messenger RNA. In chemical synthesis, scientists instead use planned cycles of protection, activation, coupling, and washing to make a defined sequence [2,4].

Why the direction of synthesis matters

Most chemical peptide synthesis builds the chain from the C-terminus to the N-terminus. That means the carboxyl end is anchored first, and each new amino acid is added to the growing amino end [1,2].

This C-to-N direction is different from how ribosomes make proteins in cells, which is N-to-C. The direction affects which protecting groups, resins, and cleavage steps are used [2,4].

What are the main methods of peptide synthesis?

Peptide synthesis can be done by solid-phase chemistry, liquid-phase chemistry, hybrid methods, enzymatic steps, native chemical ligation, or recombinant biosynthesis. The best method depends on peptide length, complexity, scale, purity needs, and cost [2,3,4].

Solid-phase peptide synthesis (SPPS)

Robert Bruce Merrifield described solid-phase peptide synthesis (SPPS) in 1963, changing peptide chemistry by keeping the growing chain attached to a solid resin [1]. This lets chemists wash away excess reagents after each step instead of isolating the peptide repeatedly.

SPPS is widely used because it is direct and automatable. Its trade-off is that every step must be efficient; small errors can build up over many cycles, so final purification and identity testing are essential [2,3].

Liquid-phase peptide synthesis (LPPS)

Liquid-phase peptide synthesis, or LPPS, builds peptides in solution. It can be useful for selected fragments or industrial routes where intermediates can be isolated and checked [3,4].

LPPS can give strong control over each intermediate, but it may take more time and purification work. For many modern peptides, manufacturers use SPPS, LPPS, or a hybrid route based on the molecule’s chemistry [3,4].

Hybrid, chemo-enzymatic, native chemical ligation, and recombinant approaches

Some peptides are too long or complex for a simple one-chain SPPS route. In those cases, chemists may make fragments and join them, use native chemical ligation, add enzyme-catalyzed steps, or use recombinant biosynthesis [4,5].

Native chemical ligation was described by Dawson and colleagues in 1994 and helped expand chemical access to larger peptide and protein targets [5]. Recombinant biosynthesis is different: living cells make the peptide or protein, followed by purification and testing [4].

How does solid-phase peptide synthesis work, step by step?

SPPS works through repeated cycles: resin loading, protecting-group removal, amino-acid activation, coupling, washing, and then repeating. After the full sequence is built, the peptide is cleaved from the resin, purified, checked, and dried, often by lyophilization [1,2,3].

1. 1Resin selection and loading: The first amino acid is attached to a solid resin. The resin affects yield, swelling, cleavage conditions, and the final C-terminal group [2].
2. 2Deprotection: A protecting group is removed so the next amino acid can react. The two classic strategies are Fmoc and Boc [2].
3. 3Activation and coupling: The next protected amino acid is chemically activated so it can form a peptide bond with the growing chain [2,3].
4. 4Washing: Extra reagents and side products are washed away while the peptide stays attached to the resin [1,2].
5. 5Repeat cycles: The deprotection, coupling, and washing cycle repeats until the full sequence is assembled [1,2].
6. 6Cleavage: The finished peptide is released from the resin, and side-chain protecting groups are removed [2,3].
7. 7Purification and drying: The crude peptide is purified, often by HPLC, then dried by lyophilization to make a stable powder for further manufacturing [2,3].

Fmoc vs Boc protecting groups

An Fmoc protecting group is removed under basic conditions, while a Boc protecting group is removed under acidic conditions. Fmoc chemistry is common in modern SPPS because its final cleavage conditions are often less harsh than classic Boc workflows [2,3].

Both systems are tools, not quality guarantees. A well-made peptide still needs testing for sequence identity, purity, water content, counterions, residual solvents, and microbial safety when it is intended for medical use [2,9,10].

Purification by HPLC and lyophilization

High-performance liquid chromatography, or HPLC purification, separates the desired peptide from closely related impurities. Mass spectrometry then helps confirm that the purified material has the expected molecular mass [2,3].

After purification, the peptide solution may be freeze-dried by lyophilization. This removes water under low temperature and vacuum, creating a dry powder that can be stored or used in later sterile manufacturing steps [2,3].

How are peptide drugs like semaglutide and tirzepatide made?

Semaglutide and tirzepatide are synthetic peptide-based medicines that act on incretin pathways. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a GLP-1/GIP receptor agonist. FDA-approved products have specific labeled uses, warnings, contraindications, and adverse effects [6,7,8].

Semaglutide is marketed as Ozempic and Wegovy. Ozempic is FDA-approved for type 2 diabetes and certain cardiovascular and kidney-risk indications in adults with type 2 diabetes, while Wegovy is FDA-approved for chronic weight management and certain cardiovascular-risk reduction uses in specific patients [6,7].

Tirzepatide is marketed as Mounjaro and Zepbound. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity, based on the FDA-approved labeling [8].

Liraglutide is another synthetic GLP-1 receptor agonist marketed as Victoza and Saxenda. Victoza is FDA-approved for type 2 diabetes, and Saxenda is FDA-approved for chronic weight management in specific patients [11,12].

These medicines may support outcomes for their labeled uses, but they also have safety limits. Semaglutide, tirzepatide, and liraglutide labels include warnings or precautions such as gastrointestinal adverse reactions, pancreatitis, gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, kidney injury related to dehydration, and contraindications for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [6,7,8,11,12].

Why GLP-1 medications are synthetic peptides

GLP-1 medicines are based on peptide hormone biology. Drug makers modify peptide sequences so the medicine lasts longer in the body than natural GLP-1, which is broken down quickly [6,7,8].

For example, semaglutide’s FDA labeling describes it as a GLP-1 receptor agonist with albumin binding, which helps extend its duration of action. The label also lists known adverse reactions, including nausea, vomiting, diarrhea, abdominal pain, and constipation for Wegovy [7].

From bulk API to finished injection

At pharmaceutical scale, a peptide drug starts as an active pharmaceutical ingredient, or API. The API must be made, purified, tested, and then formulated into a finished product such as a sterile injection or prefilled pen under drug-manufacturing controls [6,7,8,9].

The finished medicine is more than the peptide sequence. It includes concentration control, pH, excipients, container compatibility, sterility controls, and labeling that explains approved uses, dosing schedules, contraindications, warnings, and adverse effects [6,7,8,9].

Brand vs compounded semaglutide via 503A pharmacies

Compounded semaglutide via a 503A pharmacy is not FDA-approved as a finished drug, even when prepared by a licensed pharmacy. In general, 503A pharmacies compound medications for an identified patient based on a valid prescription and must follow federal and state requirements [13].

A common question is whether a compounding pharmacy “synthesizes” semaglutide. Usually, the pharmacy does not make the peptide API from amino acids; it compounds a patient-specific preparation from pharmaceutical ingredients and performs pharmacy-level quality steps required for sterile compounding [9,13].

The same distinction applies to compounded tirzepatide via a 503A pharmacy. It is not FDA-approved as a finished drug, and it requires a licensed clinician’s evaluation and prescription. Chia is one telehealth option that can connect eligible patients with clinician-reviewed access to compounded GLP-1 medications through licensed 503A pharmacy partners.

What quality controls make a synthesized peptide safe to use?

Quality control is what separates a tested medical product from an unknown powder. For patient use, peptide identity, purity, sterility, bacterial endotoxins, strength, and container quality all matter [9,10,13].

A peptide can have the right name on the vial but still be unsafe if it contains the wrong sequence, deletion products, residual solvents, microbial contamination, too much endotoxin, or an unexpected salt form. Testing reduces these risks but does not make an unapproved product FDA-approved [9,10,13].

HPLC purity, mass spec identity, and endotoxin testing

HPLC can estimate peptide purity by separating the main peptide from related impurities. Mass spectrometry can confirm molecular identity by checking mass against the expected structure [2,3].

For injectable products, sterility and endotoxin testing are especially important. USP standards for sterile compounding address practices designed to reduce contamination risk in compounded sterile preparations [9].

Counterions, net peptide content, and sterility

Many synthetic peptides are isolated as salts. One common salt form is a trifluoroacetate (TFA) counterion, which can remain after TFA-based cleavage or purification workflows [2,3].

Net peptide content matters because a vial’s weight may include water, salts, and counterions, not only active peptide. For prescription use, strength, sterility, and labeling must be controlled through appropriate drug or pharmacy systems [9,10,13].

Can you synthesize peptides at home?

DIY peptide synthesis is unsafe for human use. Peptide synthesis uses reactive chemicals, specialized equipment, purification systems, identity testing, sterility controls, and trained staff. A home setup cannot verify medical-grade purity, sterility, dose strength, or endotoxin safety [2,9,10].

Even if a sequence looks simple online, the final material may contain missing-amino-acid impurities, wrong stereochemistry, chemical residues, bacterial contamination, or inaccurate concentration. Injecting or ingesting such material can be dangerous [9,10].

Research-use-only peptides vs prescription peptides

Research-use-only peptides are sold for laboratory research, not human use. They are not equivalent to FDA-approved medicines or compounded prescriptions prepared for a specific patient by a licensed pharmacy [10,13].

This is especially important for longevity peptides such as BPC-157 or thymosin beta-4 class products. These peptides are not FDA-approved for longevity, recovery, anti-aging, or general wellness uses, and products sold outside the prescription system may not meet medical sterility, strength, or identity standards [10,13].

BPC-157 and thymosin beta-4 class products have been investigated in preclinical or limited research settings, but they are not FDA-approved for human longevity, recovery, or wellness uses. Some bulk drug substances are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026; readers should check FDA.gov for the latest regulatory status [14].

How do you legally get a synthesized peptide medication?

Prescription peptide medications are accessed through a licensed clinician and a legitimate pharmacy. The path may involve an FDA-approved brand product, a generic when available, or a compounded medication when legally appropriate for an identified patient [6,7,8,13].

FDA-approved brand peptides

FDA-approved peptide-based medicines have reviewed labeling that lists indications, dose schedules, contraindications, warnings, and adverse reactions. Examples include semaglutide products Ozempic and Wegovy, tirzepatide products Mounjaro and Zepbound, and liraglutide products Victoza and Saxenda [6,7,8,11,12].

These products may support outcomes for their approved uses, but they are not right for everyone. A clinician should screen for pregnancy status, gallbladder or pancreas history, kidney risks, diabetes medications, thyroid cancer risk, and other factors listed in the prescribing information [6,7,8,11,12].

Compounded peptides through licensed 503A pharmacies

A 503A compounding pharmacy prepares a medication for an individual patient after receiving a valid prescription. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before they are dispensed [13].

Compounding can be appropriate in certain clinical situations, but it should not be confused with buying unknown peptides online. A legitimate compounded prescription involves a licensed prescriber, patient-specific review, pharmacy oversight, and applicable sterile-compounding standards [9,13].

Getting a clinician evaluation online

Telehealth can be a legal way to start a clinician evaluation, depending on your state, medical history, and the medication being considered. The clinician may ask about weight history, diabetes status, blood pressure, pregnancy plans, current medications, allergies, and prior side effects before deciding whether a prescription is appropriate [6,7,8,13].

If a prescription is written, it should be filled by a licensed pharmacy. Avoid sellers that skip medical screening, market research-use-only peptides for human use, or cannot provide clear pharmacy and prescriber information [10,13].

Frequently asked questions about peptide synthesis

Keep reading

GLP-1 Weight Loss

How to Get Weight Loss Injections: A Step-by-Step Guide

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect

Peptides

USA Peptides: What “Research-Only” Means and Legal Ways to Access Peptides